Immunome Statistics
Total Valuation
Immunome has a market cap or net worth of $1.40 billion. The enterprise value is $1.13 billion.
Important Dates
The next estimated earnings date is Monday, November 17, 2025, after market close.
| Earnings Date | Nov 17, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunome has 87.05 million shares outstanding. The number of shares has increased by 73.92% in one year.
| Current Share Class | 87.05M |
| Shares Outstanding | 87.05M |
| Shares Change (YoY) | +73.92% |
| Shares Change (QoQ) | +9.57% |
| Owned by Insiders (%) | 2.21% |
| Owned by Institutions (%) | 86.17% |
| Float | 70.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 92.40 |
| Forward PS | n/a |
| PB Ratio | 5.19 |
| P/TBV Ratio | 5.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 90.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.13, with a Debt / Equity ratio of 0.02.
| Current Ratio | 12.13 |
| Quick Ratio | 11.72 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -81.20% and return on invested capital (ROIC) is -44.93%.
| Return on Equity (ROE) | -81.20% |
| Return on Assets (ROA) | -40.20% |
| Return on Invested Capital (ROIC) | -44.93% |
| Return on Capital Employed (ROCE) | -69.69% |
| Revenue Per Employee | $106,686 |
| Profits Per Employee | -$1.80M |
| Employee Count | 118 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +31.56% in the last 52 weeks. The beta is 2.18, so Immunome's price volatility has been higher than the market average.
| Beta (5Y) | 2.18 |
| 52-Week Price Change | +31.56% |
| 50-Day Moving Average | 12.26 |
| 200-Day Moving Average | 9.85 |
| Relative Strength Index (RSI) | 61.42 |
| Average Volume (20 Days) | 1,255,010 |
Short Selling Information
The latest short interest is 15.24 million, so 17.50% of the outstanding shares have been sold short.
| Short Interest | 15.24M |
| Short Previous Month | 15.47M |
| Short % of Shares Out | 17.50% |
| Short % of Float | 21.52% |
| Short Ratio (days to cover) | 8.51 |
Income Statement
In the last 12 months, Immunome had revenue of $12.59 million and -$212.39 million in losses. Loss per share was -$2.94.
| Revenue | 12.59M |
| Gross Profit | -120.20M |
| Operating Income | -190.53M |
| Pretax Income | -212.39M |
| Net Income | -212.39M |
| EBITDA | -188.42M |
| EBIT | -190.53M |
| Loss Per Share | -$2.94 |
Full Income StatementBalance Sheet
The company has $268.04 million in cash and $4.14 million in debt, giving a net cash position of $263.89 million or $3.03 per share.
| Cash & Cash Equivalents | 268.04M |
| Total Debt | 4.14M |
| Net Cash | 263.89M |
| Net Cash Per Share | $3.03 |
| Equity (Book Value) | 269.27M |
| Book Value Per Share | 3.09 |
| Working Capital | 254.55M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$178.68 million and capital expenditures -$53.57 million, giving a free cash flow of -$232.25 million.
| Operating Cash Flow | -178.68M |
| Capital Expenditures | -53.57M |
| Free Cash Flow | -232.25M |
| FCF Per Share | -$2.67 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,513.45% |
| Pretax Margin | -1,687.08% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunome does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -73.92% |
| Shareholder Yield | -73.92% |
| Earnings Yield | -15.18% |
| FCF Yield | -16.60% |
Analyst Forecast
The average price target for Immunome is $24.89, which is 55.08% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $24.89 |
| Price Target Difference | 55.08% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 98.16% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Immunome has an Altman Z-Score of 13 and a Piotroski F-Score of 2.
| Altman Z-Score | 13 |
| Piotroski F-Score | 2 |
